Host Dr. Alan S. Brown is joined by Kevin C. Maki, PhD, FNLA, Chief Science Officer of Biofortis Clinical Research. Dr. Maki will review obesity, metabolic syndrome and type 2 diabetes mellitus as they are all insulin resistant states and are often characterized by atherogenic dyslipidemia or the "lipid triad" of elevated triglycerides, low HDL cholesterol and a predominance of small, dense LDL particles.
Obesity, Diabetes and the Metabolic Syndrome
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Host Dr. Alan S. Brown is joined by Kevin C. Maki, PhD, FNLA, Chief Science Officer of Biofortis Clinical Research. Dr. Maki will review obesity, metabolic syndrome and type 2 diabetes mellitus as they are all insulin resistant states and are often characterized by atherogenic dyslipidemia or the "lipid triad" of elevated triglycerides, low HDL cholesterol and a predominance of small, dense LDL particles.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
Love Story: Lipid Education for Women’s Heart Health
HF Management for Patients with Comorbid Conditions
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
Personalizing Care Within the RCC Treatment Paradigm
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?